Categories

Tag: Uncategorized

THCB Reader Mail

Bazian’s Tom Donald responds to critics of evidence-based-medicine in
our post discussing the company’s

new approach to the controversial field
.

"Unfortunately EBM has, in many circles, become a “dirty word” through its
  blunt application by insurers and regulators, as well as its devaluation by  groups (mostly published products) who say they’re evidence-based when they’re
  not. EBM does, however, play a critical function, as you note. So it’s time 
for a fresh start. The sullying of its reputation leads us all to evidology –
  aka EBM 2.0. Evidology recognises that “getting evidence based” requires a new
  specialisation, one which sits between the clinical front line and the bean
  counters, assuring quality care without wasteful expenditures. As a company,
  we’re working towards the day when evidology bridges the clinicians’ world to
  the bean counters’ world, allowing them to better understand each others
  needs, requirements and decisions."

Bob Mooney has this to say to critics who think too much time is spent at medical schools teaching prospective doctors to "think like entrepreneurs" and not enough on the trickier subject of teaching them how to cost-effectively treat disease.

"What you learn in school and during training is how to diagnose and to treat disease.  As Dr. Bradley observes, little attention is payed to doing so in a cost effective manner.  There are physicians who are positioned so as to have a financial incentive to order diagnostic testing."
  Most physicians, however, have no such incentive.  We see a patient and we try
  to get through the encounter without overlooking something that will cause us
  to have to face the patient months or years later having to own up to the fact
  that we missed a diagnosis.  Every office encounter presents an opportunity to
  make a mistake that is going to get us sued.  We don’t know what the MRI
  costs, what the CT scan costs, or what cost is of the exhaustive laboratory
  workup that our patient is demanding to explain why they are always tired." 

Xoova VP of Communications, Miriam Bookey was so inspired by the post on the HEALTH AFFAIRS
interview with Regina Herzlinger
that she wrote to us. (Disclosure, as
required by the unwritten Geneva convention for blogs  we now humbly disclose the fact that Xoova is a Health 2.0 sponsor.)

"I know more about my Raisin Bran than about the guy who delivered my
children or the hospital in which he practiced. That’s because there’s
no consumer market yet in health care, and these information
organizations exist only in consumer market." — Regina Herzlinger Yes, there’s a need for physician ratings, and there are resources on the
Internet that already provide that. But we need more than the nutrition label on
the side of the cereal box. We need a real connection with the doctors who
provide our care, because selecting a doctor is both an intellectual and an
emotional choice. That’s where an enhanced profile rather than a simple
directory listing can make a difference. Today we have thousands of enhanced
physician profiles nationwide, and in time, Xoova aims to be the most popular,
trafficked site for doctors to communicate directly to patients. Today they can
do this by updating their own profiles, offering forms for download, and adding
online appointment scheduling…for free. Soon we’ll incorporate the consumer
voice in moderated testimonials, along with physician to physician referrals.
Hopefully, this will take us a step further to the world Herzlinger envisions in
which we know as much about the person who, say, performs our mastectomy as we
know about the restaurant that prepares our dinner …"

Continue reading…

TECH: First Opinion–mysterious but now rich

I’ve heard about this company but despite a couple of half-hearted efforts to get in touch never figured out what First Opinion did.

The First Opinion system is a medical knowledge-based system designed to give medical advice to the general public. Using Internet, wireless, interactive voice response, and automatic speech technologies, as well as three new authoring languages, the First Opinion system encodes a highly useful core of expert and general practitioner diagnostic and treatment knowledge into a computer system that can be accessed by non-medically trained personnel. <SNIP> The First Opinion system provides up-to-date medical advice for approximately 200 of the most commonly encountered problems in general practice and emergency medicine. If a chronic disease is diagnosed, the diagnostic system can refer the patient to the First Opinion system’s automated disease management system. The system also transmits a full report of the interaction to the patient and the patient’s physician. It can also provide valuable information to the public on numerous additional medical topics.

But at least someone was paying attention. Last week Healthways paid $22.3m for the company.

Meanwhile Healthways itself has seen its stock go on a tear the last few days. Anyone out there have a theory as to why?  It can’t have been just Gordon Norman’s bullish views on DM—or was it just the Kramer effect once more?

Healthways

Anyone knowing any more about either story, let the rest of us know in the comments.

 

QUALITY/POLICY: Sicko, Deloitte and the reason for EBM

The Deloitte Center for Health Care is best known for being headed by Paul Keckley, recently of the Center for Evidence Based Medicine at Vanderbilt, and a minor actor in Michael Moore’s recent spat with CNN. (CNN didn’t come clean that Keckley has consulted for lots of health plans and, horror of horrors, is a Republican).  I personally thought that Moore won that spat pretty convincingly, in that CNN couldn’t spend 12 seconds googling Paul.

The joke is that some of what Paul said was exactly what Moore said. Health care that is free at the point of care is not without cost, as it’s paid for out of general taxation (or some variant of it). Of course, it’s pretty shallow to say Americans don’t like paying tax, but then ignore the fact that they are otherwise (via reduced wages) forced to pay a "private tax" in health costs which massively exceeds that paid in tax to governments in other countries (after all there it adds up to 10% of GDP, here 17%). And I thought Moore was pretty clear in the movie twice (once with Tony Benn in the UK, and once when he went to visit the well-off French couple) that Europeans accepted higher taxes so that they can take care of the poor. Of course they probably don’t realize that in paying higher private taxes they save money overall.

However, the good folks at Deloitte are moving on, led by Paul, to talk more about the problems within the US system, and I suspect that Paul has learned his lesson about letting CNN tape his words without being clear about what their going to do with them and how they’ll represent him.

Instead, Deloitte’s gone to Kansas. Topeka, KS to be precise. Overall Topeka is a mirror of the national average in healthcare delivery data. Their analysis done using Healthgrades’ and other data is that if hospitals in Topeka could just do a little bit better than average they could save over 150 lives a year by just performing a little better–and that in a metro of just under 230,000.

Continue reading…

PHARMA: Time to get Shakespearean at big Pharma? by The Industry Veteran

The Industry Veteran has been busy this summer, but luckily for those missing his unique view of the pharma world, he’s ba-ack. And in his purview this time is the whole issue of why Big Pharma is filling its top jobs with lawyers.

DICK: The first thing we do, let’s kill all the lawyers.

CADE: Is not this a lamentable thing, that the skin of an innocent lamb should be made parchment, that parchment, being scribbled o’er, should undo a man? Some say the bee stings: but I say, ’tis the bee’s wax; for I did but seal once to a thing, and I was never mine own man since.

Shakespeare, King Henry VI, part II: IV, ii

Late last week (July 26) Merck announced the promotion of corporate counsel Kenneth Frazier to succeed Peter Loescher as president, global human health, effectively making him the company’s chief operating officer.  Given Pfizer’s earlier decision to make their corporate counsel, Jeffrey Kindler, the CEO there, Frazier’s promotion means two Big Pharma companies within the past year have elevated lawyers to key, strategic positions.  The moves in both cases indicate the unwillingness of the respective companies to cleanly break from the unsavory and dysfunctional practices of their recent past.

By naming Kindler to the top spot, Pfizer’s board clearly desired a relatively inexperienced manager without settled attitudes toward the pharmaceutical industry.  As CEO it seemed apparent that he would move slowly and rely upon practiced hands within the company for guidance.  Kindler immediately acknowledged this when he promoted his rival for the CEO spot, CFO David Shedlarz, and publicly referred to him as his "right hand."  Such thinking among board members appears mystifying because if any pharmaceutical company requires fundamental changes to the economic model by which it conducts business, it is Pfizer.  Since the 1990s Pfizer led the industry in implementing the blockbuster, mega-company approach.  Under William Steere, an agile and precise thinker, the company grew and prospered with the strategy.  In the hands of his successor, the arrogant head of finance, Hank McKinnell, Pfizer’s capitalization declined by more than 30% while the rest of the industry ignorantly followed his long walk down a short pier.

Kindler’s claim to fame as corporate counsel consisted of his use of outside contractors to pursue foreign Viagra counterfeiters and harass them into ceasing their operations.  While serving as Pfizer’s legal counsel Kindler hired the former number-three man at the FBI to direct corporate security and together they retained companies such as the Blackwater Group, one of the largest US contractor in Iraq.  Blackwater, which maintains close ties with right wing religious groups in the US, performs the usual range of corporate security and sleuthing services.  It is also a mercenary army for hire that makes abundant use of stealth surveillance technology.

One example of Kindler’s failure to break with the blockbuster/mega-company approach appears in his dealings with third-party payers. 

Continue reading…

BLOGS: Why Blogs?

Independence Blue Cross medical director Alan Adler has written a fairly comprehensive piece on medical and health care blogging in Managed Care Magazine. It’s called Why Blogs?

QUALITY/POLICY: Medpundit right on on cancer treatment

I didn’t get around to talking about the cancer treatment article in the NY Times last weekend, but Syd at Medpundit did. And I agree with her—we should be figuring out when to say no, heartbreaking though it is. Although buying a few extra months for a 35 year old mother in my mind is different from doing it for a 93 year old (even if he was President once). Look in the comments for a note from the subject of the NY Times article.

POLICY/INTERNATIONAL: John Cohn puts the boot in….nicely

I told John Cohn a while back that he was just too nice, and that he shouldn’t engage in the pointless argument with the free-marketeers about whether we treat cancer better or worse than the Europeans—especially as we do so much worse on many other measures. But John doesn’t listen to me—instead he takes the cancer argument and uses it to stamp all over the free-marketeers. At some point the referee should step in and stop this fight…

Meanwhile here’s the real problem. Next to John’s article on the CBS site is a video of Bush, and this is the text below it:

CBS News RAW: President Bush announced new proposals for the tax code intended to improve health care. His ideas counter Democratic proposals to nationalize the system.

Please could someone at CBS or anywhere else find me an example of a democrat wanting to “nationalize” the system. “Nationalize” means the government owning the production/service a la the Post Office or UK NHS. Not even Dennis Kucinich seems to be in favor of that. So what the hell are they talking about? I don’t know but neither do they. And, as they’re controlling a major news organization’s output, that is the problem.